BRPI0821871A2 - Suspensão farmacêutica oral compreendendo paracetamol e ibuprofeno - Google Patents

Suspensão farmacêutica oral compreendendo paracetamol e ibuprofeno

Info

Publication number
BRPI0821871A2
BRPI0821871A2 BRPI0821871-4A BRPI0821871A BRPI0821871A2 BR PI0821871 A2 BRPI0821871 A2 BR PI0821871A2 BR PI0821871 A BRPI0821871 A BR PI0821871A BR PI0821871 A2 BRPI0821871 A2 BR PI0821871A2
Authority
BR
Brazil
Prior art keywords
acetaminophen
ibuprofen
oral pharmaceutical
pharmaceutical suspension
suspension
Prior art date
Application number
BRPI0821871-4A
Other languages
English (en)
Inventor
Hartley Atkinson
Austin Kiely
Original Assignee
Wockhardt Research Center
Aft Pharmaceuticals Ltd
Hartley Atkinson
Austin Kiely
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Research Center, Aft Pharmaceuticals Ltd, Hartley Atkinson, Austin Kiely filed Critical Wockhardt Research Center
Publication of BRPI0821871A2 publication Critical patent/BRPI0821871A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BRPI0821871-4A 2008-01-03 2008-01-03 Suspensão farmacêutica oral compreendendo paracetamol e ibuprofeno BRPI0821871A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/000005 WO2009083759A1 (en) 2008-01-03 2008-01-03 Oral pharmaceutical suspension comprising paracetamol and ibuprofen

Publications (1)

Publication Number Publication Date
BRPI0821871A2 true BRPI0821871A2 (pt) 2015-06-16

Family

ID=39521691

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821871-4A BRPI0821871A2 (pt) 2008-01-03 2008-01-03 Suspensão farmacêutica oral compreendendo paracetamol e ibuprofeno

Country Status (12)

Country Link
US (1) US20110124730A1 (pt)
EP (1) EP2231138A1 (pt)
JP (1) JP2011508768A (pt)
KR (1) KR20110065417A (pt)
CN (1) CN102006867A (pt)
AU (1) AU2008345456A1 (pt)
BR (1) BRPI0821871A2 (pt)
CA (1) CA2711211A1 (pt)
MA (1) MA32056B1 (pt)
MX (1) MX2010007358A (pt)
WO (1) WO2009083759A1 (pt)
ZA (1) ZA201004650B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5977672B2 (ja) * 2009-04-27 2016-08-24 ラボラトリオ デ アプリカシオネス ファルマコディナミカス，エセ．アー．Ｌａｂｏｒａｔｏｒｉｏ Ｄｅ Ａｐｌｉｃａｃｉｏｎｅｓ Ｆａｒｍａｃｏｄｉｎａｍｉｃａｓ，Ｓ．Ａ． イブプロフェンリシナートの経口投与用の懸濁液
CN101991531B (zh) * 2010-11-09 2012-06-27 武汉人福药业有限责任公司 布洛芬口服混悬液及其制备方法
JP2014521745A (ja) * 2011-08-16 2014-08-28 メルク・シャープ・アンド・ドーム・コーポレーション 安定した非晶質分散体を調製するための無機マトリックスと有機ポリマーの組み合わせの使用
FR2999934B1 (fr) * 2012-12-21 2015-02-20 Servier Lab Composition pharmaceutique sous la forme d'une suspension orale comprenant une fraction flavonoique et de la gomme xanthane
US9993497B2 (en) 2012-12-30 2018-06-12 Hadasit Medical Research Services And Development Ltd. Use of alginate compositions in preventing or reducing liver damage caused by a hepatotoxic agent
DK3069733T3 (da) * 2013-11-13 2022-11-14 National Defense Education And Res Foundation Ny acetaminophenforbindelsessammensætning uden bivirkninger for leveren
CN103961312A (zh) * 2014-05-26 2014-08-06 王学重 一种扑热息痛口服液及其制备方法
WO2016008546A1 (en) 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
DE102016203146A1 (de) 2016-02-26 2017-08-31 Ivoclar Vivadent Ag Antibakterielle Mundpflegegele
CN106361695B (zh) * 2016-08-26 2017-12-19 湖北唯森制药有限公司 一种右旋布洛芬的研磨方法及其混悬液的制备方法
WO2018192664A1 (en) 2017-04-20 2018-10-25 Hyloris Developments Sa METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF
CN114681324B (zh) * 2017-07-10 2024-05-03 盖尔凯普科技有限公司 双释放剂型胶囊及其制备方法、装置和系统
JP7346425B2 (ja) 2018-01-11 2023-09-19 セントラス セラピューティクス 疾患を治療するためのジヒドロセラミドデサチュラーゼ阻害剤
KR101926853B1 (ko) * 2018-04-13 2018-12-07 보령제약 주식회사 약학적 조성물
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
KR102145022B1 (ko) * 2018-08-14 2020-08-14 동아제약 주식회사 이부프로펜의 현탁액 조성물 및 투여 제형
SI4081187T1 (sl) * 2019-12-23 2024-03-29 Nutra Essential Otc, S.L. Tekoča sestava, obsegajoča ibuprofen in fenilefrin
US11969400B2 (en) * 2021-03-23 2024-04-30 Kumara V. Nibhanipudi Ibuprofen for symptomatic treatment of diarrheas in HIV patients
CA3242401A1 (en) * 2021-12-28 2023-07-06 Mark Robert Zonfrillo Methods and kits for treating fever in children with combined ibuprofen and acetaminophen
IL324832A (en) 2023-06-02 2026-01-01 Ioulia Tseti Pharmaceutical composition comprising ibuprofen
WO2026073874A1 (en) * 2024-10-02 2026-04-09 Farmalíder, S.A. Ibuprofen arginate oral solution

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0109281A1 (en) * 1982-11-15 1984-05-23 The Upjohn Company Compositions comprising flurbiprofen or ibuprofen
US4788220A (en) * 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
NZ234143A (en) * 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
US5409709A (en) * 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
US5712310A (en) * 1996-06-14 1998-01-27 Alpharma Uspd, Inc. Suspension of substantially water-insoluble drugs and methods of their manufacture
ATE543491T1 (de) * 2004-07-07 2012-02-15 Aft Pharmaceuticals Ltd Kombinationspräparat enthaltend ibuprofen und paracetamol
WO2007069033A2 (en) * 2005-12-12 2007-06-21 Adcock Ingram Limited Pharmaceutical compositions comprising dexibuprofen, an opiate analgesic and paracetamol
CA2666582C (en) * 2006-10-20 2014-09-09 Mcneil-Ppc, Inc. Acetaminophen / ibuprofen combinations

Also Published As

Publication number Publication date
ZA201004650B (en) 2011-09-28
US20110124730A1 (en) 2011-05-26
MX2010007358A (es) 2011-05-25
CA2711211A1 (en) 2009-07-09
EP2231138A1 (en) 2010-09-29
WO2009083759A1 (en) 2009-07-09
AU2008345456A1 (en) 2009-07-09
KR20110065417A (ko) 2011-06-15
CN102006867A (zh) 2011-04-06
JP2011508768A (ja) 2011-03-17
MA32056B1 (fr) 2011-02-01

Similar Documents

Publication Publication Date Title
BRPI0821871A2 (pt) Suspensão farmacêutica oral compreendendo paracetamol e ibuprofeno
HUS2100009I1 (hu) Halauxifen-metil és piroxszulam kombinációja
HUS2000026I1 (hu) Anti-CD79b antitestek és immunkonjugátumok és alkalmazási eljárások
BRPI0822655A2 (pt) Implemento e sistema para cuidado oral
CY2018030I2 (el) Φαρμακοτεχνικη μορφη 514
HUE053357T2 (hu) Gyógyszerészeti készítmény és annak beadásai
BRPI0920082A2 (pt) forma de dosagem oral de acetaminofeno/tramadol com liberação estendida.
HUE064677T2 (hu) Citidin-analógokat tartalmazó orális készítmények és eljárások azok alkalmazására
EP2132133A4 (en) RELEASE OF PARTICULATE ACTIVE SUBSTANCES
ZA201101477B (en) Co-crystals and pharmaceutical formulations comprising the same
IL206789A (en) Substituted cyclic amide compound, a pharmaceutical composition comprising it and use of the compound or the pharmaceutical composition in the preparation of a medicament
HUE045046T2 (hu) Aminooxi-csoportot tartalmazó oligoszacharidok és azok konjugátumai
HUE051666T2 (hu) Módosított RSV F fehérjék és alkalmazásuk módszerei
BRPI0807544A2 (pt) Sólido farmacêutico e dose de vacina
PL2152237T3 (pl) Nowa kompozycja farmaceutyczna
HRP20160579T1 (hr) Spoj indola i njegova farmaceutska upotreba
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI0913822A2 (pt) forma farmacêutica oral e uso da forma farmacêutica
FI20075881L (fi) Lääketieteellinen väline ja sen valmistus
ATE542815T1 (de) Kokristalle und pharmazeutische zusammensetzungen damit
DK2352509T3 (da) Hla-g-proteiner og farmaceutiske anvendelser deraf
EP2474522A4 (en) AGOME ELITE AND PHARMACEUTICAL COMPOSITIONS THEREOF
HUE053977T2 (hu) Szilárd gyógyszer színezõanyagok orális alkalmazására és diagnosztikai felhasználásra
HRP20170959T1 (hr) Farmaceutska suspenzija
DK2190991T3 (da) SDF-1-Bindende nucleinsyrer og anvendelsen deraf

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.